Acerca de Cardiac Dimensions Cardiac Dimensions es un líder en el desarrollo de tratamientos innovadores, mínimamente invasivos para el tratamiento de la insuficiencia cardíaca y enfermedades cardiovasculares relacionadas. Los principales inversores de esta compañía privada incluyen Aperture Venture Partners, Arboretum Ventures, HostPlus, Life Sciences Partners, Luminara Ventures y M.H. Carnegie & Co. Cardiac Dimensions tiene su sede central en Kirkland, Washington y cuenta con oficinas en Estados Unidos, Australia y Alemania. Para más información, visite cardiacdimensions.com [https://c212.net/c/link/?t=0&l=es&o=2730087-1&h=2625617346&u...].
CONTACTO CON LOS MEDIOS DE COMUNICACIÓN: Rick Wypych rwypych@cardiacdimensions.com[mailto:rwypych@cardiacdimensions.com] (425) 605-5910
1. Witte K, et al, A Randomized Sham-Controlled Study of Percutaneous Mitral Annuloplasty in Functional Mitral Regurgitation: The REDUCE FMR Trial. J Am Coll Cardiol, HF I, DOI: 10.1016/j,jchf.2019.06.011 2. Lipiecki J, Kaye DM, Witte KK, et al. Long-Term Survival Following Transcatheter Mitral Valve Repair: Pooled Analysis of Prospective Trials with the Carillon Device. Cardiovascular Revascularization Medicine. Advance online publication [https://c212.net/c/link/?t=0&l=es&o=2730087-1&h=1632508715&u... %2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2730087-1%26h%3D29031123 42%26u%3Dhttps%253A%252F%252Fwww.sciencedirect.com%252Fscience%252Farticl e%252Fpii%252FS1553838920300828%253Fvia%25253Dihub%26a%3DAdvance%2Bonline %2Bpublication&a=Advance+online+publication]. doi:10.1016/j.carrev.2020.02.012. 3. Ponikowski P, Anker SD, AlHabib KF et al. Heart failure: preventing disease and death worldwide. ESC Heart Failure. 2014;1:4-25. 4. Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the Impact of Heart Failure in the United States. Circ Heart Fail. 2013;6(3):606-19. 5. Hoppe UC, Brandt MC, Degen H, et al. Percutaneous mitral annuloplasty device leaves free access to cardiac veins for resynchronization therapy. Catheter Cardiovasc Interv. 2009;74(3):506-11. 6. Latib, A. "Coronary Sinus Annuloplasty." New York, Montefiore Medical Center. 7. Lipiecki J, Siminiak T, Sievert H, et al. Coronary sinus-based percutaneous annuloplasty as treatment for functional mitral regurgitation: the TITAN II trial. BMJ Open Heart. 2016; 3 8. Siminiak T, et. al. Treatment of functional mitral regurgitation by percutaneous annuloplasty: Results of the TITAN Trial. Eur J Heart Fail. 2012;14:931-38. 9. Sievert, H. 2018. REDUCE-FMR: A Sham Controlled Randomized Trial of Transcatheter Indirect Mitral Annuloplasty in Heart Failure Patients with Functional Mitral Regurgitation. Presented at TCT 2018, San Diego, CA.
Cardiac Dimensions, Carillon y Carillon Mitral Contour System son marcas comerciales registradas en EE.UU. Cardiac Dimensions, Pty Ltd
https://mma.prnewswire.com/media/444446/Cardiac_Dimensions_C... [https://mma.prnewswire.com/media/444446/Cardiac_Dimensions_C...]
https://mma.prnewswire.com/media/444443/Cardiac_Dimensions_L... [https://mma.prnewswire.com/media/444443/Cardiac_Dimensions_L...]
Foto -- https://mma.prnewswire.com/media/1095158/All_Cause_Mortality... [https://c212.net/c/link/?t=0&l=es&o=2730087-1&h=86520899&u=h...] Foto - https://mma.prnewswire.com/media/444446/Cardiac_Dimensions_C... [https://c212.net/c/link/?t=0&l=es&o=2730087-1&h=3769902540&u...] Logotipo - https://mma.prnewswire.com/media/444443/Cardiac_Dimensions_L... [https://c212.net/c/link/?t=0&l=es&o=2730087-1&h=336144688&u=...]
Sitio Web: https://cardiacdimensions.com/